Laurence Tisi, Co-founder of Lumora, has been leading operations since 2003 and CEO since 2007, directing the R&D pipeline and day to day running of the company. He has helped Lumora raise £4.3M via three rounds of equity funding, generated £1.3M in revenue and over £500K in grant money. Laurence is driving the 'collaborative out-licensing' business model of the company, as it expands into the clinical sector. He is a former winner of the 'Marlene Deluca Prize' for the research he performed on bioluminescence whilst at Cambridge University. He is a named inventor on several patents including Lumora's core 'BART' technology.
Hayden joined Lumora in 2013 as Commercial Director with a remit to further commercialise Lumora’s BART (Bioluminescent Assay in Real Time) technology. Hayden brings a wealth of experience from the molecular diagnostics industry which will be crucial to fulfilling Lumora’s strategy of licensing its technology to major commercial partners. Before joining Lumora, Hayden was Divisional Director–Diagnostic Products at Lab21, and previously worked atInvitron, Gen-Probe and Molecular Light Technology.
Rob acts as a consultant to Lumora and is also Chief Financial Officer of Altacor Limited, an ophthalmology company. Rob has 20 years of professional and commercial experience providing strategic, financial and corporate finance advice to Boards and shareholders, especially in the pharmaceutical and technology industries, to maximise shareholder value. Previous roles include Chief Financial and Commercial Officer of Warwick Ventures Limited, the Technology Transfer Office of the University of Warwick, Chief Financial Officer of an AIM-listed drug development company and Senior Manager, Corporate Finance at PricewaterhouseCoopers. Rob is a Fellow of the Institute of Chartered Accountants in England and Wales, and holds a BA (Hons) in Accounting and Financial Analysis.